{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:20:11Z","timestamp":1789154411347,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Stevens\u2013Johnson syndrome and toxic epidermal necrolysis are severe mucocutaneous reactions with high morbidity and mortality, most commonly triggered by prescribed medications. Here we report a case of a 33-year-old female who developed Stevens\u2013Johnson\/toxic epidermal necrolysis after receiving an IV vitamin infusion containing glutathione, vitamin C, and vitamin D. While not commonly associated with the development of Stevens\u2013Johnson syndrome, glutathione has been previously reported to have been the inciting agent in Stevens\u2013Johnson syndrome cases. Concerns over glutathione\u2019s association with Stevens\u2013Johnson syndrome have led the FDA in the Republic of the Philippines to issue a warning over the potential associations between glutathione and Stevens\u2013Johnson syndrome. With the rise in relatively unregulated IV hydration clinics in the United States, where IV vitamin infusions are frequently completed, our case highlights the potential severe risks. In addition, our case highlights the need for providers to complete a thorough review of a patient\u2019s history, including inquiring about hydration and wellness center infusions, when trying to determine potential inciting factors in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis.<\/jats:p>","DOI":"10.1093\/jbcr\/iraf027","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:20:20Z","timestamp":1741188020000},"page":"652-655","source":"Crossref","is-referenced-by-count":6,"title":["Intravenous Glutathione and Vitamin Supplementation Causing Stevens\u2013Johnson Syndrome: A Case Report"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7816-0491","authenticated-orcid":false,"given":"Jessica S","family":"Johnson","sequence":"first","affiliation":[{"name":"Cleveland Clinic Lerner School of Medicine , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R","family":"Jarvis","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Cleveland Clinic Foundation , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April M","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cleveland Clinic Foundation , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin E","family":"Dvorak","sequence":"additional","affiliation":[{"name":"Department of Surgery, MetroHealth Medical Center , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,9]]},"reference":[{"key":"2025081301370991300_CIT0001","article-title":"Research GV North America IV Hydration Therapy Market Size Report 2030"},{"key":"2025081301370991300_CIT0002","article-title":"FDA highlights concerns with compounding of drug products by medical offices and clinics under insanitary conditions","author":"FDA","year":"2021"},{"key":"2025081301370991300_CIT0003","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1097\/DER.0000000000000782","article-title":"Glutathione whitening pills induced toxic epidermal necrolysis: an unusual case confirmed by enzyme-linked immunospot assay and liquid chromatography-mass spectrometry","volume":"32","author":"Chottawornsak","year":"2021","journal-title":"Dermatitis"},{"key":"2025081301370991300_CIT0004","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025081301370991300_CIT0005","doi-asserted-by":"crossref","first-page":"949520","DOI":"10.3389\/fmed.2022.949520","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed\/MEDLINE case reports from 1980 to 2020","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025081301370991300_CIT0006","doi-asserted-by":"crossref","first-page":"100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025081301370991300_CIT0007","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis-ABCD-10","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025081301370991300_CIT0008","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2025081301370991300_CIT0009","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.burns.2017.09.015","article-title":"Improving mortality outcomes of Stevens Johnson syndrome\/toxic epidermal necrolysis: a regional burns centre experience","volume":"44","author":"Nizamoglu","year":"2018","journal-title":"Burns"},{"key":"2025081301370991300_CIT0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"2025081301370991300_CIT0011","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jbcr\/irx016","article-title":"How does SCORTEN score","volume":"39","author":"Zavala","year":"2018","journal-title":"J Burn Care Res"},{"key":"2025081301370991300_CIT0012","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/ejcn.2017.132","article-title":"Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function","volume":"72","author":"Sinha","year":"2018","journal-title":"Eur J Clin Nutr"},{"key":"2025081301370991300_CIT0013","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5826\/dpc.0801a04","article-title":"Glutathione for skin lightening: a regnant myth or evidence-based verity","volume":"8","author":"Sonthalia","year":"2018","journal-title":"Dermatol Pract Concept"},{"key":"2025081301370991300_CIT0014","first-page":"177","article-title":"Efficacy of intravenous glutathione vs. placebo for skin tone lightening","volume":"26","author":"Zubair","year":"2016","journal-title":"J Pak Assoc Dermatol"},{"key":"2025081301370991300_CIT0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3390\/nu11051056","article-title":"Impact of supplementary amino acids, micronutrients, and overall diet on glutathione homeostasis","volume":"11","author":"Gould","year":"2019","journal-title":"Nutrients"},{"key":"2025081301370991300_CIT0016","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.burns.2015.12.001","article-title":"Burn unit care of Stevens Johnson syndrome\/toxic epidermal necrolysis: a survey","volume":"42","author":"Le","year":"2016","journal-title":"Burns"},{"key":"2025081301370991300_CIT0017","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1097\/CM9.0000000000003250","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: updates in pathophysiology and management","volume":"137","author":"Hasegawa","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"2025081301370991300_CIT0018","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"2025081301370991300_CIT0019","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s13555-023-00928-w","article-title":"Biologic TNF-alpha inhibitors for Stevens\u2013Johnson syndrome, toxic epidermal necrolysis, and TEN-SJS overlap: a study-level and patient-level meta-analysis","volume":"13","author":"Cao","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025081301370991300_CIT0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.anai.2022.05.009","article-title":"Etanercept treatment of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"129","author":"Tian","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025081301370991300_CIT0021","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"2025081301370991300_CIT0022","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/1744666X.2020.1740591","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies","volume":"16","author":"Lin","year":"2020","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/iraf027\/62350486\/iraf027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/46\/3\/652\/62350486\/iraf027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/46\/3\/652\/62350486\/iraf027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:37:19Z","timestamp":1755063439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/46\/3\/652\/8064631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,9]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,9]]},"published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/iraf027","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,9]]}}}